Latest Conference

Data from the IGNITE4 phase 3 trial supports the use of eravacycline for the treatment of complicated intra-abdominal infections (cIAI), including infections caused by pathogens resistant to other antibiotics.

New software unveiled last month suggests hospitals could make patient-specific predictions of antibiotic susceptibility.

An outbreak of infections caused by the drug-resistant fungus, Candida auris, in one United Kingdom hospital has been linked to multi-use patient equipment.

Julia E. Szymczak, PhD, shares the results of her study which revealed that fear drives some clinicians to prescribe inappropriately.

This emotional drive carried throughout the continuum of the prescribing pathway, from initial prescription to stopping or de-escalating antibiotics.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

Investigational beta-lacatamase inhibitor IMI/REL demonstrates a favorable overall response against certain imipenem-non-susceptible bacterial infections.

Dr. Gonzalo Bearman delves into the use of contact precautions for endemic pathogens such as MRSA and VRE and assesses the effectiveness of this approach.

Researchers present positive new data from multiple studies of VIBATIV at the 2018 ECCMID conference in Madrid, Spain.

Researchers present preliminary case series of confirmed cases of hepatitis A virus at Detroit Medical Center as Michigan struggles with ongoing outbreak.

According to recent research from Johns Hopkins Medicine, when it comes to making choices on appropriate antibiotic prescribing, outpatient providers are making the decision based on patient demand, not necessarily on what's actually appropriate for the condition.

Mike Kohut, PhD shares the results of his research that reveals providers are writing prescriptions for infections based largely on patient demand and not guideline recommendations.

Previously seen in Wisconsin in 2015-2016, Elizabethkingia seems to have made its way to the Empire state.

Emil Lesho, DO, FACP, FIDSA, FSHEA, explains what makes Elizabethkingia unique.

A recent survey explores prevention practices for Legionnaires’ disease and water management programs in health care facilities.

Dr. Thomas Sandora shares recent data on screening for asymptomatic carriage of Clostridium difficile and provides insight into what the preferred first-line treatment for the infection in children.

Contagion® Editorial Advisory Board member, James S. Lewis, PharmD, FIDSA, shares how antibiotic stewards can craft stewardship interventions to their own reality.

Kari Simonsen, MD, and Matthew Linam, MD debate the best way to measure and improve hand hygiene compliance.

In the SHEA Spring 2018 Opening Plenary, Zintars Beldavs stresses the importance of communication and collaboration in the fight against antimicrobial resistance.

Researchers compare CLABSIs attributed to CRE in short-term acute care hospitals with long-term acute care hospitals using data reported to NHSN in 2015-2016.

PIV infections are not as rigorously studied as CLABSIs, but they should be.

Contagion® will be covering the conference, and so, keep a look out for session coverage as well as interviews with some of the key presenters.

The FDA grants Fast Track designation to TAK-426, Takeda’s purified, inactivated, alum-adjuvanted whole Zika virus vaccine candidate.

Daniel Diekema, MD, explains how clinicians can actively work to prevent pathogen spread in their health care facilities.

Pedro Cahn, MD, describes the risk associated with raltegravir HD.

Michael Edmond, MD, MPH, MPA, stresses that a collaborative effort is needed to control C. difficile in hospitals.

Pedro Cahn, MD, explains who the target population is for raltegravir HD.

Daniel Diekema, MD, describes recent developments made in rapid and molecular diagnostic testing in the microbiology lab, and how these tests strengthen infection prevention efforts.